How AI is Revolutionizing Precision Medicine: Episode 65 of the Precision Medicine Podcast with Dr. Douglas Flora
Douglas Flora, President-Elect at Association of Cancer Care Centers, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, shared a post by Karan Cushman, Chief Vision Officer at Cushman Creative, on LinkedIn, adding:
“It’s Time to Drive Smarter Cancer Care
Why do we continue adhering to arbitrary standards like “age 50” for cancer screening when risk factors vary dramatically between individuals? Consider the 48-year-old firefighter left vulnerable by current guidelines despite elevated occupational risks.
The future of cancer care demands personalized risk assessment: identifying those at highest risk and providing targeted, timely screening that could save lives.
Our podcast discussions with Karan about polygenic risk scores and early cancer detection (ECD/MCED) are eloquently expanded upon in Eric Topol‘s insightful Substack article. Eric shared these concepts with me during our fireside chat last year, and they resonated so deeply that I requested permission to reprint his thoughts on the topic in our journal AI in Precision Oncology a few months ago:
Karan Cushman, thank you for recognizing the value of these ideas and using your platform to amplify this crucial conversation about risk-stratified cancer screening.”
Quoting Karan Cushman‘s post:
“Why are we still screening for cancer like it’s 1999?
At last week’s Community Oncology Alliance Conference, AI in cancer care was a major theme – and for good reason. It has the potential to not only improve treatment, but to rethink prevention entirely.
In Episode 65 of the Precision Medicine Podcast, I talk with COA panelist Douglas Flora, about how AI can help us rethink cancer screening entirely.
Right now, 88 out of 100 women screened for breast cancer will never develop it, yet we screen them all the same—ignoring better ways to identify who’s truly at risk.
Together, Dr. Flora and Sanjay Juneja, break down how AI can help us personalize screening, prevent overtesting, and catch disease earlier in the people who need it most—before symptoms, before scans, and ideally, before they ever need an oncologist.
Tune in to hear how smarter screening could be AI’s next big breakthrough in oncology.”
Proceed to the video attached to the post.
More posts featuring Douglas Flora on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023